Name of License:
Avanzarx Pharmaceutical Holdings, LLCBy the:
Department of Veterans Affairs, Office of Research and Development (VA)On:
Jul 22, 2021Summary
VA intends to offer Avanzarx Pharmaceutical Holdings, LLC an exclusive license to technology called "Treatment of Pulmonary Fibrosis using NEU1 Salidase Inhibitors" by Goldblum et al., VA ID 2019-175
Tech Name:
Treatment of Pulmonary Fibrosis using NEU1 Salidase InhibitorsAction:
IntentDates:
July 22, 2021 through August 6, 2021Address:
U.S. Department of Veterans Affairs
Technology Transfer Program (14RDTT)
810 Vermont Ave, NW
Washington, DC 20420For further information contact
David Marks
U.S. Department of Veterans Affairs
Technology Transfer Program (14RDTT)
810 Vermont Ave, NW
Washington, DC 20420
Office: 202-443-5609
email: david.marks2@va.gov